Merck: Business Analysis Merck is a flourishing research-driven pharmaceutical company‚ which discovers‚ develops‚ manufacturers‚ and promotes an extensive variety of human and animal health products. Although Merck is one of the biggest pharmaceutical companies of the world‚ they still come across problems today while striving to sustain a lead against its competition. Merck has achieved success with its lengthy history of breakthrough drugs and the development of three significant pharmaceutical
Premium Human resource management Pharmaceutical industry Human resources
MERCK: OPEN FOR INNOVATION? Founded in 1891 as an American subsidiary of his German namesake‚ Merck was once considered the “undisputed king of the pharmaceutical industry with ground‐ breaking drugs”(The Chief Executive 2003). But for the last decade‚ Merck has gone through a period of stagnation; it began to lose exclusivity patents on blockbuster drugs and has witnessed Pfizer’s rise to top place in the industry. It seemed now that internal R&D that was once the company’s main asset would
Premium Pharmaceutical industry
First established in 1668 in Darmstadt‚ Germany‚ Merck is currently (in 1978) one of the largest prescription drug producers in the world. After coming off a 10 year drug drought in the late 1970s‚ Merck put a large amount of money into research to continue its dominance in the prescription drug industry. The research-first approach worked and since then Merck has increased sales significantly. Merck’s mission was well stated by founder George W. Merck. “We try never to forget that medicine is for
Premium Pharmacology Onchocerciasis Pharmaceutical industry
2011). In 1978‚ Merck‚ while testing invermectin (a parasite killing drug for animals)‚ found that invermectin killed a parasite similar to the one that caused river blindness. The problem for Merck was that river blindness generally only affects people in very poor areas and there was very little chance to recoup their financial investment by selling the drug. The ethical dilemma represented by this situation is focused on what course of action Merck should take. Does Merck invest precious resources
Premium Ethics Decision making Onchocerciasis
Merck‚ the FDA‚ and the VIOXX Recall MBA 520-D4C2 Ethics & Leadership in a Global Environment April 22‚ 2012 Merck and Vioxx Recall Did Merck act in social and ethical manner? In 2005‚ Merck was ranked fourth in sales among pharmaceutical companies. Merck had released the drug Vioxx‚ for treating Osteoarthritis in late 1990. Merck as a company has a reputation of being one of the most ethical and
Premium Marketing Brand Management
On what basis would you rank them in importance? The stakeholders in the Merk case is the people infected with river blindness‚ the community affected by river blindness‚ the employees of Merk‚ the company itself‚ and the Stockholders. In order of importance: 1. The infected people 2. The company 3. Stockholders 4. The employees 5. Community affected by river blindness What are the potential costs and benefits of such an investment? The Scientists were encouraging Merk to invest in further research
Premium Integrity Pharmaceutical drug Onchocerciasis
In the year 2000‚ Merck produced a controversial product called Vioxx. Four years later it gained worldwide attention because of the drug’s potential cardiovascular risks. This was detrimental to the company’s reputation because it was alleged Merck knowingly distributed Vioxx despite its risk. Both Barbara Martinez and Anne W. Mathews of the Wall Street Journal wrote articles into the investigation of Vioxx. Their article suggests Merck knew the dangers of Vioxx at an early stage of its clinical
Premium Clinical trial
EXECUTIVE SUMMARY Statement of the Problem Merck & Co.‚ Inc.‚ a leading pharmaceutical company‚ faces the threat of the patents of its most popular drugs expiring in 2002. The only way to counter the loss of sales from these drugs going off patent is to develop new drugs in order to refresh the company’s portfolio. LAB Pharmaceuticals‚ a small pharmaceutical company who specializes in the treatment of neurological disorders‚ has approached Merck with the opportunity to license Davanrik‚ a new
Premium Patent Pharmacology Pharmaceutical drug
Introduction and Situational Analysis Merck and River Blindness ethical dilemma is whether to pursue research that may or may affect the profits‚ or to choose a safer choice and go for profit rather than researching the drug. The outcome from researching the drug could possibly lead to healing the deadly and dangerous disease known as River Blindness. This drug is known to kill the parasite that has caused the disease. The problem with this situation was that the consumers of the drug could not pay
Premium Pharmacology Medicine Ethics
Financial Management Agenda 1. What is the WACC and why is it important to estimate a firm’s cost of capital? Do you agree with Joanna Cohen’s WACC calculation? Why or why not? 2. If you do not agree with Cohen’s analysis‚ calculate your own WACC for Nike and justify your assumptions. 3. Calculate the costs of equity using CAPM‚ the dividend discount model‚ and the earnings capitalization ratio. What are the advantages and disadvantages of each method? 4. What should Kimi Ford recommend regarding
Premium Arithmetic mean Weighted average cost of capital Average